Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026)

Sagimet Biosciences' Income from Continuing Operations history spans 5 years, with the latest figure at 10650000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 41.41% to 10650000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 43512000.0 through Mar 2026, up 23.82% year-over-year, with the annual reading at 51038000.0 for FY2025, 12.01% down from the prior year.
  • Income from Continuing Operations came in at 10650000.0 for Q1 2026, down from 9568000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6357000.0 in Q3 2023 to a low of 18176000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 8135000.0 (2023), against an average of 9806187.5.
  • Year-over-year, Income from Continuing Operations tumbled 174.19% in 2025 and then surged 41.41% in 2026.
  • Sagimet Biosciences' Income from Continuing Operations stood at 7195000.0 in 2022, then fell by 13.3% to 8152000.0 in 2023, then tumbled by 98.74% to 16201000.0 in 2024, then surged by 40.94% to 9568000.0 in 2025, then fell by 11.31% to 10650000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Income from Continuing Operations are 10650000.0 (Q1 2026), 9568000.0 (Q4 2025), and 12908000.0 (Q3 2025).